The 91st annual Medical Economics physician salary survey shows that physicians in five medical specialties earned less in 2019, than in 2018. Learn more in this slideshow.
Rheumatology Network Editorial Staff
In this week's news roundup, we highlight two studies that examine risks associated with biologics used to treat rheumatic disease. We also highlight the 2020 treatment guidelines for gout issued this week by the American College of Rheumatology. In today's video, we feature an interview with John D. Fitzgerald, M.D., Ph.D., chief of rheumatology at Ronald Reagan UCLA Medical Center in Santa Monica. Dr. Fitzgerald served as the corresponding author of the guidelines.
Physicians from New York University Langone Health report in the New England Journal of Medicine that the baseline use of biologics was not associated with worse outcomes in a group of 14 patients with autoimmune disease who contracted COVID-19.
Researchers writing in JAMA Dermatology this week report that patients with inflammatory bowel disease, rheumatoid arthritis, and psoriasis who are treated with biologics may have a "clinically meaningful" increase in melanoma risk, but the jury is still out.
In this interview with Dr. Kamalan Jeevaratnam, a cardiac electrophysiologist with the Faculty of Health and Medical Sciences at the University of Surrey, we explore whether bisphosphonates are associated with atrial fibrillation. “There are a group of studies that show bisphosphonates are proarrhythmic and a group that show they do not cause any problem,” he said in this interview with Rheumatology Network from his home in London.
The American College of Rheumatology has updated its treatment guidelines for gout. The guideline includes 42 treatment recommendations, of which 16 are now strongly recommended. They address standard treat-to-target urate lowering therapy, the use of allopurinol and more. In this slideshow, we highlight the 16 strongest recommendations.
The American College of Rheumatology has issued new treatment guidelines for gout strongly supporting a treat-to-target strategy for urate lowing therapy with a serum urate target of less than 6 mg/dl.
In this week's Rheumatology Network news roundup, we highlight an interview we conducted with Brian LaMoreaux, M.D., M.S., a medical director at Horizon Therapeutics and a volunteer clinical rheumatologist with CommunityHealth in Chicago. In this interview, he shares his experience as a rheumatologist in a community where healthcare is not always easy to come by.
Stress from the possibility of infection can wreak havoc on the mental health and physical well-being of rheumatic disease patients. It usually affects patients in two ways: they either become experts at thwarting infectious disease or they succumb to the stress. In this video, Dr. Kim Gorgens offers tips for identifying stress and anxiety in your patients.
Dr. Robinson heads the COVID-19 registry for the Global Rheumatology Alliance, a group that is tracking COVID-19 cases in rheumatology patients worldwide. The group recently published the first set of data from registry in the journal Lancet Rheumatology. In this interview, Dr. Robinson discusses the role of the registry.